Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Capecitabine+endocrine therapy|DRUG: Placebo+endocrine therapy
Sponsor: Henan Cancer Hospital